138 related articles for article (PubMed ID: 32714997)
1. Evaluation of D-isomer of
Hirai N; Watabe T; Nagamori S; Wiriyasermkul P; Tanaka Y; Romanov V; Naka S; Kanai Y; Liu Y; Tani N; Sakai T; Tatsumi M; Shimosegawa E; Kanai Y; Hatazawa J
Asia Ocean J Nucl Med Biol; 2020; 8(2):102-108. PubMed ID: 32714997
[TBL] [Abstract][Full Text] [Related]
2. (18)F-FBPA as a tumor specific tracer of L-type amino acid transporter 1 (LAT1): PET evaluation in tumor and inflammation compared to (18)F-FDG and (11)C-methionine.
Watabe T; Hatazawa J
Hell J Nucl Med; 2015; 18 Suppl 1():149. PubMed ID: 26665232
[TBL] [Abstract][Full Text] [Related]
3.
Watabe T; Ikeda H; Nagamori S; Wiriyasermkul P; Tanaka Y; Naka S; Kanai Y; Hagiwara K; Aoki M; Shimosegawa E; Kanai Y; Hatazawa J
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):321-331. PubMed ID: 27550420
[TBL] [Abstract][Full Text] [Related]
4. Distribution of LAT1-targeting PET tracer was independent of the tumor blood flow in rat xenograft models of C6 glioma and MIA PaCa-2.
Aoki M; Watabe T; Nagamori S; Naka S; Ikeda H; Kongpracha P; Horitsugi G; Kanai Y; Shimosegawa E; Kanai Y; Hatazawa J
Ann Nucl Med; 2019 Jun; 33(6):394-403. PubMed ID: 30820863
[TBL] [Abstract][Full Text] [Related]
5. Correlation between L-amino acid transporter 1 expression and 4-borono-2-
Kashihara T; Mori T; Nakaichi T; Nakamura S; Ito K; Kurihara H; Kusumoto M; Itami J; Yoshimoto S; Igaki H
Cancer Med; 2023 Nov; 12(21):20564-20572. PubMed ID: 37881128
[TBL] [Abstract][Full Text] [Related]
6. Preliminary feasibility study on differential diagnosis between radiation-induced cerebral necrosis and recurrent brain tumor by means of [
Beshr R; Isohashi K; Watabe T; Naka S; Horitsugi G; Romanov V; Kato H; Miyatake SI; Shimosegawa E; Hatazawa J
Ann Nucl Med; 2018 Dec; 32(10):702-708. PubMed ID: 30194665
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of LAT1 Expression in Patients With Lung Cancer and Mediastinal Tumors: 18F-FBPA PET Study With Immunohistological Comparison.
Watabe T; Ose N; Naka S; Fukui E; Kimura T; Kanou T; Funaki S; Sasaki H; Kamiya T; Kurimoto K; Isohashi K; Tatsumi M; Shimosegawa E; Kato H; Ohgaki R; Kanai Y; Shintani Y
Clin Nucl Med; 2023 Oct; 48(10):853-860. PubMed ID: 37682600
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of D-isomers of 4-borono-2-
Kanazawa M; Nishiyama S; Hashimoto F; Kakiuchi T; Tsukada H
EJNMMI Res; 2018 Jun; 8(1):47. PubMed ID: 29900520
[TBL] [Abstract][Full Text] [Related]
9. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.
Wiriyasermkul P; Nagamori S; Tominaga H; Oriuchi N; Kaira K; Nakao H; Kitashoji T; Ohgaki R; Tanaka H; Endou H; Endo K; Sakurai H; Kanai Y
J Nucl Med; 2012 Aug; 53(8):1253-61. PubMed ID: 22743251
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Potential of FBPA-PET/CT Imaging for Colorectal Cancer and its Liver Metastases Expressing LAT1.
Minoji T; Takahashi H; Watabe T; Ishikawa S; Kato H; Ohgaki R; Kanai Y; Sekido Y; Hata T; Hamabe A; Ogino T; Miyoshi N; Uemura M; Yamamoto H; Doki Y; Eguchi H
Anticancer Res; 2023 Sep; 43(9):3913-3921. PubMed ID: 37648310
[TBL] [Abstract][Full Text] [Related]
11. Practical calculation method to estimate the absolute boron concentration in tissues using
Watabe T; Hanaoka K; Naka S; Kanai Y; Ikeda H; Aoki M; Shimosegawa E; Kirihata M; Hatazawa J
Ann Nucl Med; 2017 Jul; 31(6):481-485. PubMed ID: 28439784
[TBL] [Abstract][Full Text] [Related]
12. Predominant contribution of L-type amino acid transporter to 4-borono-2-(18)F-fluoro-phenylalanine uptake in human glioblastoma cells.
Yoshimoto M; Kurihara H; Honda N; Kawai K; Ohe K; Fujii H; Itami J; Arai Y
Nucl Med Biol; 2013 Jul; 40(5):625-9. PubMed ID: 23557719
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 4-borono-2-18F-fluoro-L-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma-bearing rat model.
Wang HE; Liao AH; Deng WP; Chang PF; Chen JC; Chen FD; Liu RS; Lee JS; Hwang JJ
J Nucl Med; 2004 Feb; 45(2):302-8. PubMed ID: 14960653
[TBL] [Abstract][Full Text] [Related]
14. 4-Borono-2-
Ishiwata K
Ann Nucl Med; 2019 Apr; 33(4):223-236. PubMed ID: 30820862
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption.
Hsieh CH; Chen YF; Chen FD; Hwang JJ; Chen JC; Liu RS; Kai JJ; Chang CW; Wang HE
J Nucl Med; 2005 Nov; 46(11):1858-65. PubMed ID: 16269600
[TBL] [Abstract][Full Text] [Related]
17. Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET.
Havu-Aurén K; Kiiski J; Lehtiö K; Eskola O; Kulvik M; Vuorinen V; Oikonen V; Vähätalo J; Jääskeläinen J; Minn H
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):87-94. PubMed ID: 16896669
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic analysis and uptake of 18F-FBPA-Fr after ultrasound-induced blood-brain barrier disruption for potential enhancement of boron delivery for neutron capture therapy.
Yang FY; Chang WY; Li JJ; Wang HE; Chen JC; Chang CW
J Nucl Med; 2014 Apr; 55(4):616-21. PubMed ID: 24525207
[TBL] [Abstract][Full Text] [Related]
19. Advantages of FBPA PET in evaluating early response of anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice: Comparison to FDG PET.
Tatsumi M; Soeda F; Naka S; Kurimoto K; Ooe K; Fukui H; Katayama D; Watabe T; Kato H; Tomiyama N
Front Oncol; 2022; 12():1026608. PubMed ID: 36620558
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of (S)-2-amino-3-[3-(2-
Nozaki S; Nakatani Y; Mawatari A; Hume WE; Doi H; Watanabe Y
EJNMMI Res; 2023 Apr; 13(1):36. PubMed ID: 37115356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
